REGN3470 + REGN3471 +REGN3479

Unassigned

New Medicines

Ebola virus infection - treatment

Information

New molecular entity
Not Known
Regeneron

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A fixed dose combination of three monoclonal antibodies, REGN 3470, REGN 3471 and REGN 3479 for the treatment of Ebola virus infection, using proprietary rapid response technologies [1].
Natural Ebola outbreaks occur most often in African countries, the most recent from 2014 through 2016. According to the World Health Organization, during that outbreak more than 28,600 cases of Ebola virus infection were suspected, probable or confirmed and more than 11,000 people died [2].
Ebola virus infection - treatment
Intravenous